

**Global Radiopharmaceuticals-Nuclear Medicine Market: By Product Type (Diagnostic Radiopharmaceuticals (SPECT Radiopharmaceuticals and PET Radiopharmaceuticals) and Therapeutic Radiopharmaceuticals (Beta Emitters, Alpha emitters, Brachytherapy, and Others)), By Application (Oncology, Neurological disorders, Cardiovascular diseases, Thyroid, and Others), By Route of Administration (Oral, Inhalation, and Parenteral) By End User (Hospitals, Clinics, Diagnostic Centers, and Research Institutes), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) - Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023**

<https://marketpublishers.com/r/GEAB2796DEEEN.html>

Date: September 2017

Pages: 204

Price: US\$ 4,400.00 (Single User License)

ID: GEAB2796DEEEN

## **Abstracts**

Global Radiopharmaceuticals/ Nuclear Medicine Market Report Description:

Global radiopharmaceuticals/nuclear medicine market report gives comprehensive outlook on radiopharmaceuticals across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). The report on radiopharmaceuticals/nuclear medicine market gives historical, current, and future market sizes (US\$ Mn) on the basis of product type, application

area, route of administration, end user, and geographic regions. This report studies radiopharmaceuticals/nuclear medicine market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, radiopharmaceuticals/nuclear medicine market report includes new product introductions; regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed radiopharmaceuticals market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the radiopharmaceuticals/nuclear medicine market report include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in manufacturing, supply and prescribing of radiopharmaceuticals.

#### Global Radiopharmaceuticals/Nuclear Medicine Market:

Global radiopharmaceuticals market estimated to be valued US\$ 5,146 Mn in 2017 and poised to grow at CAGR of 8.9% over 2017-2023. Market for radiopharmaceuticals projected to reach US\$ 8,564 Mn by 2023 owing to increasing adoption in radio therapeutic and diagnostic procedures across the globe.

Growing prevalence of cancer and cardiovascular diseases expected to drive adoption of radiopharmaceuticals across the globe

The global radiopharmaceutical market is growing at a significant CAGR due to rising in the prevalence of various types of cancers and cardiovascular diseases. The growing prevalence of various cancers resulted into increased adoption of radiopharmaceuticals in diagnosis and treatment of several cancers in developed economies. For instance, according to globocan cancer statistics, There were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6 million people living with cancer (within 5 years of diagnosis) in 2012 worldwide. Moreover, advances in technology such as introduction of PET radiotracers and targeted radio immunotherapies expected to drive the overall market revenue growth over the forecast period

Emergence of radiopharmaceuticals as safer alternative to the conventional diagnosis

The development of effective radiopharmaceuticals for diagnosis and treatment expected to drive the market revenue growth over the forecast period. The advances in imaging devices with radio-activity are aiding healthcare professionals in effective diagnosis. Moreover, radio-imaging diagnosis is considered as effective alternative to

the conventional diagnosis techniques such as X-rays which expected to boost the market demand for diagnostic radiopharmaceuticals across the globe. In addition, increase in the healthcare expenditure, radiopharmaceuticals abundance, and non-invasiveness in the treatment and diagnostic procedure might bolster the nuclear medicine market over the forecast period.

North America accounts for larger revenue share in global radiopharmaceuticals market

North America market holds the higher revenue share in global radiopharmaceuticals market and projected to remain same over the forecast period owing to rising FDA approvals and production of radiopharmaceuticals in the region. Asia-Pacific radiopharmaceuticals market projected to grow at significant CAGR over the forecast period in comparison with other regions owing to conducive business environment and rising PET installations in the region

## **COMPETITION ASSESSMENT**

Key players profiles in the global Radiopharmaceuticals market include:

Advanced Accelerator Applications S.A. (France)

Bayer AG (Germany)

Bracco Imaging S.p.A (Italy)

Cardinal Health, Inc. (U.S.)

Eli Lilly and Co. (U.S.)

GE Healthcare (U.S.)

IBA Molecular Imaging (Belgium)

Jubilant Life Sciences Ltd (India)

Lantheus Medical Imaging, Inc. (U.S.)

Mallinckrodt plc (Ireland)

Navidea Biopharmaceutical (U.S.)

Nordion, Inc. (Canada)

Siemens Healthineers (Germany)

Players in the radiopharmaceuticals market are focusing on expanding product portfolio, acquisitions to garner larger market revenue share in global radiopharmaceuticals market.

### **KEY FINDINGS OF THE REPORT:**

Global Radiopharmaceuticals market expanding at 8.9% CAGR over 2017 to 2023 to reach market value of US\$ 8,564 Mn by 2023

Based on product type, diagnostic radiopharmaceuticals accounted for larger market revenue share in 2016 owing to wider application in various diagnostic procedures across the regions and expected to grow at significant rate

Oncology application segment accounted for larger market revenue share in 2016 expected to remain attractive over the forecast period owing to growing prevalence of various cancers

Players are focusing on production of radiopharmaceuticals to expand market presence in global radiopharmaceuticals market.

### **KEY FEATURES OF THE REPORT:**

The report provides granular level information about the market size, regional market share, historic market (2012-2016) and forecast (2017-2023)

The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies

The report outlines drivers, restraints, unmet needs, and trends that are

currently affecting the market

The report tracks recent innovations, key developments and startup's details that are actively working in the market

The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis in addition to recent technology advancements and innovations in the market

## **DETAILED SEGMENTATION**

### **By Product Type**

Diagnostic Radiopharmaceuticals

SPECT Radiopharmaceuticals

PET Radiopharmaceuticals

Therapeutic Radiopharmaceuticals

Beta Emitters

Alpha emitters

Brachytherapy

Others

### **By Application**

Oncology

Neurological disorders

Cardiovascular diseases

Thyroid

Others

#### By Route of Administration

Oral

Inhalation

Parenteral

#### By End User

Hospitals

Clinics

Diagnostic Centers

Research Institutes

#### Geography

North America

U.S

Canada

Europe

Germany

France

U.K

Italy

Spain

Russia

Poland

Rest of Europe

Asia-Pacific

Japan

China

India

Australia & New Zealand

ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia,  
and Others)

South Korea

Rest of Asia-Pacific

Latin America

Brazil

Mexico

Argentina

Venezuela

Rest of Latin America

Middle East and Africa (MEA)

Gulf Cooperation Council (GCC) Countries

Israel

South Africa

Rest of MEA



## Contents

### **1. RESEARCH METHODOLOGY**

- 1.1. Secondary and Primary research
  - 1.1.1. Secondary Sources
  - 1.1.2. Primary Sources
- 1.2. Market Revenue Estimation Methodology
- 1.3. Key Assumptions
- 1.4. Acronyms

### **2. SCOPE OF STUDY**

- 2.1. Market Definition
- 2.2. Objective of the Research
- 2.3. Regions covered in the study

### **3. EXECUTIVE SUMMARY**

### **4. GLOBAL RADIOPHARMACEUTICALS/NUCLEAR MEDICINE MARKET DYNAMICS**

- 4.1. Drivers
  - 4.1.1. Economic Drivers
  - 4.1.2. Demand Side Drivers
  - 4.1.3. Supply Side Drivers
- 4.2. Restraints
- 4.3. Opportunities/Unmet Needs of the Market
- 4.4. Trends

### **5. UNIQUE FEATURES OF THE REPORT**

- 5.1. Competition analysis
- 5.2. Regulatory landscape
- 5.3. PESTLE analysis
- 5.4. Porter's analysis

### **6. GLOBAL RADIOPHARMACEUTICALS/NUCLEAR MEDICINE MARKET ANALYSIS, BY PRODUCT TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023**

#### 6.1. Diagnostic Radiopharmaceuticals (SPECT Radiopharmaceuticals and PET Radiopharmaceuticals)

6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

#### 6.2. Therapeutic Radiopharmaceuticals (Beta Emitters, Alpha emitters, Brachytherapy, and Others)

6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

### **7. GLOBAL RADIOPHARMACEUTICALS/NUCLEAR MEDICINE MARKET FORECAST, BY APPLICATION ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

#### 7.1. Oncology

7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

#### 7.2. Neurological disorders

7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

#### 7.3. Cardiovascular diseases

7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

#### 7.4. Thyroid

7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

#### 7.5. Others

7.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

### **8. GLOBAL RADIOPHARMACEUTICALS/NUCLEAR MEDICINE MARKET FORECAST, BY ROUTE OF ADMINISTRATION ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

#### 8.1. Oral

8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

#### 8.2. Inhalation

8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

8.3. Parenteral

8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

**9. GLOBAL RADIOPHARMACEUTICALS/NUCLEAR MEDICINE MARKET  
FORECAST, BY END USER ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

9.1. Hospitals

9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

9.2. Clinics

9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

9.3. Diagnostic Centers

9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

9.4. Research Institutes

9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

**10. RADIOPHARMACEUTICALS/NUCLEAR MEDICINE MARKET ANALYSIS, BY  
REGION, 2012 - 2016 AND FORECAST, 2017 - 2023**

10.1. North America Radiopharmaceuticals/Nuclear Medicine Market Analysis, 2012 -  
2016 and Forecast, 2017 - 2023

10.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue  
(USD Mn) and Y-o-Y Growth (%)

10.1.1.1. Diagnostic Radiopharmaceuticals

10.1.1.1.1. SPECT Radiopharmaceuticals

10.1.1.1.2. PET Radiopharmaceuticals

10.1.1.2. Therapeutic Radiopharmaceuticals

10.1.1.2.1. Beta Emitters

10.1.1.2.2. Alpha emitters

10.1.1.2.3. Brachytherapy

10.1.1.2.4. Others

10.1.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue  
(USD Mn) and Y-o-Y Growth (%)

10.1.2.1. Oncology

- 10.1.2.2. Neurological disorders
- 10.1.2.3. Cardiovascular diseases
- 10.1.2.4. Thyroid
- 10.1.2.5. Others
- 10.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
  - 10.1.3.1. Oral
  - 10.1.3.2. Inhalation
  - 10.1.3.3. Parenteral
- 10.1.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
  - 10.1.4.1. Hospitals
  - 10.1.4.2. Clinics
  - 10.1.4.3. Diagnostic Centers
  - 10.1.4.4. Research Institutes
- 10.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
  - 10.1.5.1. U.S.
  - 10.1.5.2. Canada
- 10.2. Europe Radiopharmaceuticals/Nuclear Medicine Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
  - 10.2.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    - 10.2.1.1. Diagnostic Radiopharmaceuticals
      - 10.2.1.1.1. SPECT Radiopharmaceuticals
      - 10.2.1.1.2. PET Radiopharmaceuticals
    - 10.2.1.2. Therapeutic Radiopharmaceuticals
      - 10.2.1.2.1. Beta Emitters
      - 10.2.1.2.2. Alpha emitters
      - 10.2.1.2.3. Brachytherapy
      - 10.2.1.2.4. Others
  - 10.2.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    - 10.2.2.1. Oncology
    - 10.2.2.2. Neurological disorders
    - 10.2.2.3. Cardiovascular diseases
    - 10.2.2.4. Thyroid
    - 10.2.2.5. Others
  - 10.2.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by

## Revenue (USD Mn) and Y-o-Y Growth (%)

### 10.2.3.1. Oral

### 10.2.3.2. Inhalation

### 10.2.3.3. Parenteral

## 10.2.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

### 10.2.4.1. Hospitals

### 10.2.4.2. Clinics

### 10.2.4.3. Diagnostic Centers

### 10.2.4.4. Research Institutes

## 10.2.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

### 10.2.5.1. U.K

### 10.2.5.2. Germany

### 10.2.5.3. France

### 10.2.5.4. Italy

### 10.2.5.5. Spain

### 10.2.5.6. Russia

### 10.2.5.7. Poland 10.2.5.8. Rest of Europe

## 10.3. Asia-Pacific Radiopharmaceuticals/Nuclear Medicine Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023

### 10.3.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

#### 10.3.1.1. Diagnostic Radiopharmaceuticals

##### 10.3.1.1.1. SPECT Radiopharmaceuticals

##### 10.3.1.1.2. PET Radiopharmaceuticals

#### 10.3.1.2. Therapeutic Radiopharmaceuticals

##### 10.3.1.2.1. Beta Emitters

##### 10.3.1.2.2. Alpha emitters

##### 10.3.1.2.3. Brachytherapy

##### 10.3.1.2.4. Others

### 10.3.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

#### 10.3.2.1. Oncology

#### 10.3.2.2. Neurological disorders

#### 10.3.2.3. Cardiovascular diseases

#### 10.3.2.4. Thyroid

#### 10.3.2.5. Others

### 10.3.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by

## Revenue (USD Mn) and Y-o-Y Growth (%)

### 10.3.3.1. Oral

### 10.3.3.2. Inhalation

### 10.3.3.3. Parenteral

## 10.3.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

### 10.3.4.1. Hospitals

### 10.3.4.2. Clinics

### 10.3.4.3. Diagnostic Centers

### 10.3.4.4. Research Institutes

## 10.3.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

### 10.3.5.1. Japan

### 10.3.5.2. China

### 10.3.5.3. India

### 10.3.5.4. ASEAN

### 10.3.5.5. Australia & New Zealand 10.3.5.6. Rest of Asia-Pacific

## 10.4. Latin America Radiopharmaceuticals/Nuclear Medicine Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023

### 10.4.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

#### 10.4.1.1. Diagnostic Radiopharmaceuticals

##### 10.4.1.1.1. SPECT Radiopharmaceuticals

##### 10.4.1.1.2. PET Radiopharmaceuticals

#### 10.4.1.2. Therapeutic Radiopharmaceuticals

##### 10.4.1.2.1. Beta Emitters

##### 10.4.1.2.2. Alpha emitters

##### 10.4.1.2.3. Brachytherapy

##### 10.4.1.2.4. Others

### 10.4.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

#### 10.4.2.1. Oncology

#### 10.4.2.2. Neurological disorders

#### 10.4.2.3. Cardiovascular diseases

#### 10.4.2.4. Thyroid

#### 10.4.2.5. Others

### 10.4.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

#### 10.4.3.1. Oral

10.4.3.2. Inhalation

10.4.3.3. Parenteral

10.4.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

10.4.4.1. Hospitals

10.4.4.2. Clinics

10.4.4.3. Diagnostic Centers

10.4.4.4. Research Institutes

10.4.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

10.4.5.1. Brazil

10.4.5.2. Mexico

10.4.5.3. Argentina

10.4.5.4. Venezuela

10.4.5.5. Rest of Latin America

10.5. Middle East & Africa (MEA) Radiopharmaceuticals/Nuclear Medicine Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023

10.5.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

10.5.1.1. Diagnostic Radiopharmaceuticals

10.5.1.1.1. SPECT Radiopharmaceuticals

10.5.1.1.2. PET Radiopharmaceuticals

10.5.1.2. Therapeutic Radiopharmaceuticals

10.5.1.2.1. Beta Emitters

10.5.1.2.2. Alpha emitters

10.5.1.2.3. Brachytherapy

10.5.1.2.4. Others

10.5.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

10.5.2.1. Oncology

10.5.2.2. Neurological disorders

10.5.2.3. Cardiovascular diseases

10.5.2.4. Thyroid

10.5.2.5. Others

10.5.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

10.5.3.1. Oral

10.5.3.2. Inhalation

10.5.3.3. Parenteral



#### 10.5.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

10.5.4.1. Hospitals

10.5.4.2. Clinics

10.5.4.3. Diagnostic Centers

10.5.4.4. Research Institutes

#### 10.5.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

10.5.5.1. Gulf Cooperation Council (GCC) Countries

10.5.5.2. Israel

10.5.5.3. South Africa

10.5.5.4. Rest of MEA

## 11. COMPETITION LANDSCAPE

### 11.1. Strategic Dashboard of Top Market Players

### 11.2. Company Profiles (Introduction, Financial Analysis, Component & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

11.2.1. Advanced Accelerator Applications S.A. (France)

11.2.2. Bayer AG (Germany)

11.2.3. Bracco Imaging S.p.A (Italy)

11.2.4. Cardinal Health, Inc. (U.S.)

11.2.5. Eli Lilly and Co. (U.S.)

11.2.6. GE Healthcare (U.S.)

11.2.7. IBA Molecular Imaging (Belgium)

11.2.8. Jubilant Life Sciences Ltd (India)

11.2.9. Lantheus Medical Imaging, Inc. (U.S.)

11.2.10. Mallinckrodt plc (Ireland)

11.2.11. Navidea Biopharmaceutical (U.S.)

11.2.12. Nordion, Inc. (Canada)

11.2.13. Siemens Healthineers (Germany)



## I would like to order

Product name: Global Radiopharmaceuticals-Nuclear Medicine Market: By Product Type (Diagnostic Radiopharmaceuticals (SPECT Radiopharmaceuticals and PET Radiopharmaceuticals) and Therapeutic Radiopharmaceuticals (Beta Emitters, Alpha emitters, Brachytherapy, and Others)), By Application (Oncology, Neurological disorders, Cardiovascular diseases, Thyroid, and Others), By Route of Administration (Oral, Inhalation, and Parenteral) By End User (Hospitals, Clinics, Diagnostic Centers, and Research Institutes), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) - Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Product link: <https://marketpublishers.com/r/GEAB2796DEEEN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GEAB2796DEEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970